Concomitantly, the present study demonstrated for the first time that RAD001, an inhibitor of mTOR pathway, played a significant anti‐cancer role in ESCC by targeting the vascular system, which provides a possible target and drug choice for the treatment of this cancer type. The gene discussed is MTOR; the disease is cancer.